What is the appropriate management for a 41-year-old man with a history of rickets who presents with hypocalcemia and folate deficiency?

Management of 41-Year-Old Male with History of Rickets, Hypocalcemia (7.5 mg/dL), and Folate Deficiency (2.6 ng/mL)

This patient requires immediate calcium and vitamin D repletion to correct hypocalcemia, plus folic acid supplementation for folate deficiency, while simultaneously investigating whether this represents reactivation of hereditary phosphopenic rickets (likely X-linked hypophosphataemia) versus acquired nutritional osteomalacia.

Immediate Management Priorities

Correct Hypocalcemia

• Initiate oral calcium supplementation immediately to address the serum calcium of 7.5 mg/dL (normal 8.5-10.5 mg/dL), as hypocalcemia in adults with rickets history can cause neuromuscular irritability, tetany, and cardiac complications 1
• Start calcitriol (active vitamin D) at therapeutic doses, as it enhances calcium absorption and is indicated for management of hypocalcemia in patients with metabolic bone disease 2
• Monitor for symptoms of severe hypocalcemia including paresthesias, muscle cramps, or cardiac arrhythmias, which may require urgent intervention 1

Address Folate Deficiency

• Prescribe folic acid 1 mg daily orally for the folate level of 2.6 ng/mL (normal >3 ng/mL), as this is the usual therapeutic dose for adults regardless of the underlying cause 3
• Continue treatment until clinical symptoms resolve and blood picture normalizes, then maintain at 0.4 mg daily for adults 3
• Rule out vitamin B12 deficiency before initiating doses greater than 0.1 mg, as folic acid can mask B12 deficiency anemia 3

Diagnostic Workup to Determine Rickets Etiology

First-Line Laboratory Panel

• Obtain serum phosphate, alkaline phosphatase (ALP), 25-hydroxyvitamin D, parathyroid hormone (PTH), creatinine, and bicarbonate to distinguish between phosphopenic rickets (hereditary) versus calcipenic rickets (nutritional) 4
• Low serum phosphate with elevated ALP suggests phosphopenic rickets, whereas low 25-hydroxyvitamin D with markedly elevated PTH indicates nutritional vitamin D deficiency 4
• Measure 1,25-dihydroxyvitamin D, which is low or inappropriately normal in phosphopenic rickets despite hypophosphatemia 4

Assess Renal Phosphate Handling

• Calculate tubular maximum phosphate reabsorption per GFR (TmP/GFR) using spot urine phosphate and creatinine to confirm renal phosphate wasting if phosphate is low 4
• Obtain spot urine calcium and creatinine, as low urinary calcium is typical in active rickets and helps differentiate from other causes 4
• Screen urine for amino acids, glucose, and low-molecular-weight proteins to exclude Fanconi syndrome, which causes generalized tubular dysfunction rather than isolated phosphate wasting 4

Advanced Testing if Phosphopenic Rickets Suspected

• Measure intact FGF23 levels if hypophosphatemia with renal phosphate wasting is confirmed, as non-suppressed or elevated FGF23 in the setting of hypophosphatemia points toward X-linked hypophosphataemia (XLH), which accounts for approximately 80% of hereditary phosphopenic rickets 4
• Consider genetic testing for PHEX gene mutations to confirm XLH, particularly given the patient's childhood rickets history 5
• If PHEX testing is negative, sequence additional genes including DMP1, ENPP1, and FGF23 4

Screen for Complications

• Obtain imaging to assess for pseudofractures, early osteoarthritis of spine/hips/knees, and enthesopathies, which are common radiographic features in adults with XLH 6, 4
• Perform renal ultrasound to screen for nephrocalcinosis, especially if prior treatment with phosphate supplements occurred 6
• Evaluate for dental abscesses and periodontal disease, which are highly prevalent in XLH patients 6, 5

Treatment Algorithm Based on Diagnosis

If Hereditary Phosphopenic Rickets (XLH) Confirmed

• Burosumab (anti-FGF23 antibody) is the preferred treatment if available, demonstrating superior efficacy compared to conventional therapy 5
• If burosumab unavailable, initiate conventional therapy with oral phosphate supplementation (20-60 mg/kg/day elemental phosphorus divided into 4-6 doses) plus active vitamin D (calcitriol or alfacalcidol) to prevent secondary hyperparathyroidism 7, 5
• Never give phosphate supplementation alone, as this leads to secondary hyperparathyroidism and worsens bone disease 7
• Lifelong treatment is required, as discontinuation leads to recurrence of biochemical and clinical abnormalities 5

If Nutritional Rickets/Osteomalacia Confirmed

• Administer high-dose cholecalciferol or ergocalciferol daily for minimum 12 weeks followed by lifelong maintenance supplementation 1
• Ensure adequate calcium intake through diet or supplementation (typically 1000-1200 mg daily for adults) 1
• This represents the most cost-effective approach for nutritional deficiency 1

Monitoring During Treatment

Regular Follow-Up Parameters

• Monitor serum phosphate, calcium, ALP, PTH, and creatinine every 3-4 months during active treatment 5
• Track urinary calcium:creatinine ratio to detect hypercalciuria, which increases risk of nephrocalcinosis when using phosphate and active vitamin D 6, 5
• Assess for resolution of bone pain and improvement in functional status 6

Critical Pitfalls to Avoid

• Do not rely solely on FGF23 levels for routine monitoring, as assay variability and modulation by phosphate intake, vitamin D therapy, and treatment status produce misleading results 7, 4
• Avoid giving phosphate supplements together with calcium supplements or high-calcium foods like milk, as precipitation in the intestinal tract reduces absorption 6
• Do not normalize fasting serum phosphate levels as a treatment goal in XLH, as this is not achievable with conventional therapy and attempting to do so increases complications 6
• Monitor for secondary hyperparathyroidism, which results from long-term stimulation of parathyroid cells by FGF23 and phosphate supplements 6